Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2000 Feb;44(2):283-6.
doi: 10.1128/AAC.44.2.283-286.2000.

Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

Affiliations
Comparative Study

Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

H Tomioka et al. Antimicrob Agents Chemother. 2000 Feb.

Abstract

WQ-3034 is a newly synthesized acidic fluoroquinolone. We assessed its in vitro activity against Mycobacterium tuberculosis and M. avium complex using levofloxacin (LVFX), ciprofloxacin (CPFX), sparfloxacin (SPFX), and KRM-1648 (KRM) as reference drugs. The MICs of these agents were determined by the agar dilution method with 7H11 medium. The MICs at which 50 and 90% of the test strains were inhibited (MIC(50)s, and MIC(90)s, respectively) for the test quinolones for rifampin (RMP)-susceptible M. tuberculosis strains were in the order SPFX < LVFX </= WQ-3034 </= CPFX, while those for RMP-resistant M. tuberculosis strains were in the order SPFX </= WQ-3034 </= LVFX < CPFX. The MICs of KRM for RMP-susceptible M. tuberculosis were much lower than those of the test quinolones, while the MIC(90) of KRM for RMP-resistant M. tuberculosis strains was higher than those of the quinolones. The MIC(50)s and MIC(90)s of the test drugs for M. avium were in the order KRM < SPFX < CPFX </= WQ-3034 </= LVFX, while those for M. intracellulare were in the order KRM < SPFX < WQ-3034 LVFX </= CPFX. Next, we compared the antimicrobial activities of the test drugs against M. tuberculosis organisms residing in cells of the Mono Mac 6 macrophage (Mphi)-like cell line (MM6-Mphis) and of the A-549 type II alveolar cell line (A-549 cells). When drugs were added at the concentration that achieves the maximum concentration in blood, progressive killing or inhibition of the M. tuberculosis organisms residing in MM6-Mphis and A-549 cells was observed in the order KRM > SPFX >/= LVFX > WQ-3034 > CPFX. The efficacies of all quinolones against intracellular M. tuberculosis organisms were significantly lower in A-549 cells than in MM6-Mphis. WQ-3034 at the MIC caused more marked growth inhibition of intramacrophage M. tuberculosis than did LVFX. These findings indicate that the in vitro anti-M. tuberculosis activity of WQ-3034 is greater than that of CPFX and is comparable to that of LVFX.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Chemical structure of WQ-3034.
FIG. 2
FIG. 2
Antimicrobial activities of WQ-3034 (●), CPFX (▵), LVFX (▴), SPFX (□), and KRM (■) against M. tuberculosis Kurono residing in MM6-Mφs (A) and A-549 cells (B). The drugs were added to the culture medium of M. tuberculosis-infected cells at the Cmax achievable in the blood after oral administration: 3.7, 0.56, 2.0, 0.39, and 0.05 μg/ml for WQ-3034, CPFX, LVFX, SPFX, and KRM, respectively. ○, control culture without drugs. Each symbol indicates the mean ± standard error of the mean (n = 3). ∗ and ∗∗, significantly different between bacterial CFU recovered from cells treated with each comparison drug and cells treated with WQ-3034 (∗, P < 0.05; ∗∗, P < 0.01; Student's t test).

References

    1. Akaki T, Sato K, Shimizu T, Sano C, Kajitani H, Dekio S, Tomioka H. Effector molecules in expression of the antimicrobial activity of macrophages against Mycobacterium avium complex: roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. J Leukoc Biol. 1997;62:795–804. - PubMed
    1. Alangaden G J, Lerner S A. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997;25:1213–1221. - PubMed
    1. Bermudez L E, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alverolar cells. Infect Immun. 1996;64:1400–1406. - PMC - PubMed
    1. Chan J, Xing Y, Magliozzo R S, Bloom B R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med. 1992;175:1111–1122. - PMC - PubMed
    1. Chien S-C, Rogge M C, Gisclon L G, Curtin C, Wong F, Natarajan J, Williams R R, Fowler C L, Cheung W K, Chow A T. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41:2256–2260. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources